hVIVO plc (LON:HVO - Get Free Report)'s stock price traded down 46.3% during mid-day trading on Friday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). 83,062,000 shares changed hands during mid-day trading, an increase of 2,325% from the average session volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).
Wall Street Analyst Weigh In
Separately, Shore Capital reaffirmed a "buy" rating on shares of hVIVO in a research note on Friday.
View Our Latest Stock Analysis on HVO
hVIVO Price Performance
The company's 50-day moving average is GBX 16.16 and its 200-day moving average is GBX 18.13. The firm has a market capitalization of £61.56 million, a price-to-earnings ratio of 3.59 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.
hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. On average, research analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current year.
Insider Activity at hVIVO
In related news, insider Yamin Mo' Khan sold 3,062,246 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,459.93). 14.03% of the stock is owned by insiders.
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Further Reading
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
